RxDoctor Payments Data

Julie Snead, APRN

Nurse Practitioner · Manchester, NHNPI 1982655361

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 41.7% of the total. Reporting peaked in 2022 at $244 and has fallen 76.7% since, to $57 in 2025. Among nurse practitioner clinicians in NH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$616in general payments, 2019–2025

Across 26 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$257
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$108
  • Gilead$103
  • Madrigal Pharmaceuticals$64
  • Bristol Myers Squibb$33
  • Johnson & Johnson$31
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$616100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$616 in reported general payments places this provider in the 90th percentile of 714 nurse practitioner providers in New Hampshire.

See all nurse practitioner providers in New Hampshire

Medicare billing

Part B allowed, 2024
$15,323
Medicare patients
125
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$338,643
LinzessLinaclotide37$37,208
Mesalamine21$11,251
Mesalamine ErMesalamine29$6,293
Lubiprostone36$6,275
Pantoprazole Sodium248$3,116
Omeprazole91$1,533
Famotidine87$1,384
Colestipol Hcl26$854
Ondansetron OdtOndansetron26$414
Dicyclomine Hcl17$212
Ondansetron Hcl11$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$31$338,64313 claims
AbbVieLinzess$257$37,20837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 714 nurse practitioner providers in New Hampshire.

Other nurse practitioner in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →